The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a phase 2 trial of ramucirumab plus docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).
 
Kentaro Sawada
No Relationships to Disclose
 
Yasuyuki Kawamoto
Honoraria - AstraZeneca; Incyte; Lilly Japan; Merck; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Taiho Pharmaceutical
Research Funding - Japan Agency for Medical Research and Development; Takeda
 
Kazuaki Harada
Speakers' Bureau - AstraZeneca; Bayer; Bristol Myers Squibb; DAIICHI SANKYO COMPANY, LIMITED; Lilly; Merck Serono; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical
 
Takayuki Ando
No Relationships to Disclose
 
Susumu Sogabe
No Relationships to Disclose
 
Yoshimitsu Kobayashi
No Relationships to Disclose
 
Masayoshi Dazai
No Relationships to Disclose
 
Michio Nakamura
Honoraria - Bayer; Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; Merck; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Takeda (Inst); Zeria Pharmaceutical (Inst)
 
Kazuteru Hatanaka
No Relationships to Disclose
 
Atsushi Ishiguro
No Relationships to Disclose
 
Atsushi Sato
No Relationships to Disclose
 
Shintaro Nakano
No Relationships to Disclose
 
Yoshiaki Shindo
No Relationships to Disclose
 
Ayumu Hosokawa
Honoraria - Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; MSD; Nihon Zouki; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst)
 
Ken Ito
No Relationships to Disclose
 
Ayumu Yoshikawa
No Relationships to Disclose
 
Kayoko Iuchi
No Relationships to Disclose
 
Isao Yokota
Speakers' Bureau - AstraZeneca; Chugai Pharma
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD K.K; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Hokkaido Gastrointestinal Cancer Study Group (HGCSG)
No Relationships to Disclose